Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Personalized whole-genome-based ctDNA dynamics during neoadjuvant therapy across breast cancer subtypes: results from MONITOR-Breast.

Future oncology (London, England)·2026
Same author

Clinical benefit of paclitaxel/carboplatin plus bevacizumab with zoledronic acid in pulmonary epithelioid hemangioendothelioma complicated by hypertrophic pulmonary osteoarthropathy and cardiac tamponade: a case report.

Frontiers in oncology·2026
Same author

Impact of medical oncologist certification on survival outcomes in metastatic colorectal cancer: evidence from the SCRUM-Japan MONSTAR-SCREEN Observational Study.

International journal of clinical oncology·2026
Same author

Genomic landscape of immune checkpoint inhibitor-induced aplastic anemia: a case report.

Frontiers in oncology·2026
Same author

Correction: Differences in drug efficacy and prognosis between primary and metastatic sites for de novo stage IV breast cancer: an exploratory analysis of a phase III trial, JCOG1017.

Breast cancer (Tokyo, Japan)·2026
Same author

Primary tumour resection reduces the risk of major local morbidity in de novo stage IV breast cancer: secondary data analysis from the JCOG1017 randomized clinical trial.

The British journal of surgery·2026
Same journal

[A Case of Pulmonary Epithelioid Hemangioendothelioma Associated with Multiple Cancers].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[Long-Term Survival in Three Cases with Pulmonary Metastases from Colorectal Cancer Given Low-Dose S-1 Under a Regimen Combining a Carbohydrate-Restricted Ketogenic Diet, Metformin, Vitamin D, Eicosapentaenoic Acid, and Other Complementary Therapies].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[Preventive Effect of Saline Eye Wash for Eye Symptoms Due to High-Dose and Intermediate-Dose Cytarabine Therapy].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[Examination of Factors Affecting the Efficacy of Naldemedine Tosilate Tablets for Opioid-Induced Constipation].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[Recent Advances in the Treatment of HER2-Altered Solid Tumors].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[FGFR2 Fusion Gene-Positive Solid Tumors].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
See all related articles

Related Experiment Video

Updated: Jun 5, 2026

Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma
08:18

Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma

Published on: September 8, 2021

[BRAF-Mutant Solid Tumor].

Yoichi Naito1

  • 1Dept. of General Internal Medicine, National Cancer Center Hospital East.

Gan to Kagaku Ryoho. Cancer & Chemotherapy
|June 4, 2026
PubMed
Summary
This summary is machine-generated.

BRAF mutations drive cancer by activating the RAS/RAF/MEK/ERK pathway. Targeted therapies show promise across various cancers, but resistance necessitates new approaches like pan-RAF and ERK inhibitors.

More Related Videos

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells
06:09

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Published on: June 7, 2019

Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells
10:01

Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells

Published on: August 2, 2022

Related Experiment Videos

Last Updated: Jun 5, 2026

Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma
08:18

Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma

Published on: September 8, 2021

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells
06:09

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Published on: June 7, 2019

Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells
10:01

Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells

Published on: August 2, 2022

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • BRAF kinase is a critical component of the RAS/RAF/MEK/ERK (MAPK) signaling pathway, frequently acting as an oncogenic driver in diverse cancers.
  • BRAF mutations, particularly V600, lead to pathway overactivation, promoting tumor growth and survival.
  • BRAF mutations are classified into three functional classes based on signaling mechanisms and RAS dependency.

Purpose of the Study:

  • To review the role of BRAF mutations in oncogenesis.
  • To summarize the efficacy and limitations of current BRAF and MEK inhibitors.
  • To discuss emerging therapeutic strategies targeting BRAF-mutated cancers.

Main Methods:

  • Literature review of BRAF mutations and targeted therapies.
  • Analysis of clinical trial data for BRAF-targeted agents.
  • Examination of resistance mechanisms to BRAF inhibition.

Main Results:

  • BRAF/MEK inhibitors have improved outcomes in BRAF V600-mutant melanoma and show activity in other cancers like NSCLC and thyroid cancer.
  • BRAF-mutated colorectal cancer exhibits limited response to monotherapy due to EGFR feedback, necessitating combination strategies.
  • Basket trials support tumor-agnostic treatment approaches for BRAF-mutated malignancies.

Conclusions:

  • BRAF-targeted therapies, including combination strategies, offer significant clinical benefits across various cancer types.
  • Resistance to current BRAF inhibitors, often mediated by RAF dimerization, highlights the need for novel therapeutic agents.
  • Pan-RAF and ERK inhibitors are under development to overcome resistance and expand treatment options for BRAF-mutated cancers.